Recent Investment Analysts’ Ratings Updates for Boston Scientific (BSX)

Several analysts have recently updated their ratings and price targets for Boston Scientific (NYSE: BSX):

  • 7/31/2019 – Boston Scientific was given a new $50.00 price target on by analysts at Leerink Swann. They now have a “buy” rating on the stock.
  • 7/25/2019 – Boston Scientific had its price target raised by analysts at Raymond James from $48.00 to $50.00. They now have a “strong-buy” rating on the stock.
  • 7/24/2019 – Boston Scientific was given a new $46.00 price target on by analysts at Needham & Company LLC. They now have a “buy” rating on the stock.
  • 7/24/2019 – Boston Scientific was given a new $46.00 price target on by analysts at BTIG Research. They now have a “buy” rating on the stock.
  • 7/24/2019 – Boston Scientific was given a new $50.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 6/27/2019 – Boston Scientific had its price target raised by analysts at Jefferies Financial Group Inc from $44.00 to $48.00. They now have a “positive” rating on the stock.
  • 6/27/2019 – Boston Scientific had its price target raised by analysts at Piper Jaffray Companies from $42.00 to $50.00. They now have an “overweight” rating on the stock.
  • 6/27/2019 – Boston Scientific had its price target raised by analysts at Stifel Nicolaus from $44.00 to $46.00. They now have an “in-line” rating on the stock.
  • 6/27/2019 – Boston Scientific had its price target raised by analysts at Canaccord Genuity from $43.00 to $46.00. They now have a “buy” rating on the stock.
  • 6/18/2019 – Boston Scientific had its price target raised by analysts at Wells Fargo & Co from $42.00 to $45.00. They now have an “outperform” rating on the stock.

NYSE:BSX traded down $1.10 on Wednesday, reaching $41.76. 156,974 shares of the stock traded hands, compared to its average volume of 7,368,634. The firm has a market capitalization of $59.17 billion, a P/E ratio of 28.41, a price-to-earnings-growth ratio of 2.59 and a beta of 0.80. The company has a quick ratio of 1.04, a current ratio of 1.31 and a debt-to-equity ratio of 0.81. Boston Scientific Co. has a 12 month low of $31.56 and a 12 month high of $43.66. The stock’s fifty day moving average is $42.52.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.39 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.01. Boston Scientific had a net margin of 13.85% and a return on equity of 23.29%. The firm had revenue of $2.63 billion during the quarter, compared to analyst estimates of $2.64 billion. During the same period in the previous year, the business posted $0.41 earnings per share. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. As a group, research analysts predict that Boston Scientific Co. will post 1.56 EPS for the current fiscal year.

In other Boston Scientific news, SVP Xin Warren Wang sold 10,000 shares of Boston Scientific stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $38.45, for a total transaction of $384,500.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Maulik Nanavaty sold 3,039 shares of Boston Scientific stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $40.46, for a total transaction of $122,957.94. The disclosure for this sale can be found here. In the last three months, insiders sold 57,289 shares of company stock worth $2,355,050. 0.66% of the stock is currently owned by insiders.

Large investors have recently modified their holdings of the business. IFM Investors Pty Ltd lifted its holdings in shares of Boston Scientific by 12.9% in the first quarter. IFM Investors Pty Ltd now owns 90,005 shares of the medical equipment provider’s stock worth $3,454,000 after buying an additional 10,276 shares in the last quarter. Toronto Dominion Bank lifted its holdings in shares of Boston Scientific by 20.1% in the first quarter. Toronto Dominion Bank now owns 1,013,085 shares of the medical equipment provider’s stock worth $38,872,000 after buying an additional 169,323 shares in the last quarter. Somerset Group LLC lifted its holdings in shares of Boston Scientific by 2.0% in the first quarter. Somerset Group LLC now owns 52,593 shares of the medical equipment provider’s stock worth $2,019,000 after buying an additional 1,052 shares in the last quarter. Legacy Bridge LLC lifted its holdings in shares of Boston Scientific by 15.3% in the first quarter. Legacy Bridge LLC now owns 3,767 shares of the medical equipment provider’s stock worth $145,000 after buying an additional 500 shares in the last quarter. Finally, State Treasurer State of Michigan lifted its holdings in shares of Boston Scientific by 0.8% in the first quarter. State Treasurer State of Michigan now owns 399,396 shares of the medical equipment provider’s stock worth $15,329,000 after buying an additional 3,200 shares in the last quarter. 90.60% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Article: What is a good dividend yield?

Receive News & Ratings for Boston Scientific Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Co and related companies with MarketBeat.com's FREE daily email newsletter.